Sign in Subscribe

B. Riley Would Be ‘Aggressive Buyers’ of Cue Biopharma After 24% Selloff on Strong CUE-221 Data

Phase 2 CSU data favored CUE-221 over placebo and Xolair. Missing IgE/PK results and a late fade drove a 24% drop. B. Riley: Buy, $83 PT.

B. Riley Would Be ‘Aggressive Buyers’ of Cue Biopharma After 24% Selloff on Strong CUE-221 Data
Credit: Cue Biopharma
Already have an account? Sign in.